149 related articles for article (PubMed ID: 11914641)
1. Recombinant interleukin-2 treatment decreases P-glycoprotein activity and paclitaxel metabolism in mice.
Bonhomme-Faivre L; Pelloquin A; Tardivel S; Urien S; Mathieu MC; Castagne V; Lacour B; Farinotti R
Anticancer Drugs; 2002 Jan; 13(1):51-7. PubMed ID: 11914641
[TBL] [Abstract][Full Text] [Related]
2. Effect of interleukin-2 pretreatment on paclitaxel absorption and tissue disposition after oral and intravenous administration in mice.
Hosten B; Abbara C; Petit B; Dauvin A; Bourasset F; Farinotti R; Gonin P; Bonhomme-Faivre L
Drug Metab Dispos; 2008 Aug; 36(8):1729-35. PubMed ID: 18508881
[TBL] [Abstract][Full Text] [Related]
3. Recombinant interleukin-2 pre-treatment increases anti-tumor response to paclitaxel by affecting lung P-glycoprotein expression on the Lewis lung carcinoma.
Hosten B; Challuau D; Gil S; Bouquet C; Marion S; Perricaudet M; Di Palma M; Farinotti R; Bonhomme-Faivre L
Anticancer Drugs; 2006 Feb; 17(2):195-9. PubMed ID: 16428938
[TBL] [Abstract][Full Text] [Related]
4. Effect of recombinant interleukin-2 pretreatment on oral and intravenous digoxin pharmacokinetics and P-glycoprotein activity in mice.
Castagne V; Bonhomme-Faivre L; Urien S; Ben Reguiga M; Soursac M; Gimenez F; Farinotti R
Drug Metab Dispos; 2004 Feb; 32(2):168-71. PubMed ID: 14744937
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 treatment effect on imatinib pharmacokinetic, P-gp and BCRP expression in mice.
Hosten B; Abbara C; Cibert M; Petit B; Farinotti R; Gonin P; Bonhomme-Faivre L
Anticancer Drugs; 2010 Feb; 21(2):193-201. PubMed ID: 20016370
[TBL] [Abstract][Full Text] [Related]
6. Enhanced oral bioavailability of paclitaxel by recombinant interleukin-2 in mice with murine Lewis lung carcinoma.
Abbara C; Rouchon C; Hosten B; Farinotti R; Bonhomme-Faivre L
Drug Metabol Drug Interact; 2004; 20(4):219-31. PubMed ID: 15663292
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and neutrophil toxicity of paclitaxel orally administered in mice with recombinant interleukin-2.
Jamois C; Comets E; Mentré F; Marion S; Farinotti R; Bonhomme-Faivre L
Cancer Chemother Pharmacol; 2005 Jan; 55(1):61-71. PubMed ID: 15378273
[TBL] [Abstract][Full Text] [Related]
8. A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979).
Callies S; de Alwis DP; Harris A; Vasey P; Beijnen JH; Schellens JH; Burgess M; Aarons L
Br J Clin Pharmacol; 2003 Jul; 56(1):46-56. PubMed ID: 12848775
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.
Liu X; Sun J; Chen X; Wang S; Scott H; Zhang X; Zhang Q
J Pharm Pharmacol; 2012 Jun; 64(6):775-82. PubMed ID: 22571255
[TBL] [Abstract][Full Text] [Related]
11. Estradiol regulation of P-glycoprotein expression in mouse kidney and human tubular epithelial cells, implication for renal clearance of drugs.
Kanado Y; Tsurudome Y; Omata Y; Yasukochi S; Kusunose N; Akamine T; Matsunaga N; Koyanagi S; Ohdo S
Biochem Biophys Res Commun; 2019 Nov; 519(3):613-619. PubMed ID: 31540689
[TBL] [Abstract][Full Text] [Related]
12. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance.
Vredenburg MR; Ojima I; Veith J; Pera P; Kee K; Cabral F; Sharma A; Kanter P; Greco WR; Bernacki RJ
J Natl Cancer Inst; 2001 Aug; 93(16):1234-45. PubMed ID: 11504769
[TBL] [Abstract][Full Text] [Related]
13. Effect of interleukin-2 on intestinal P-glycoprotein expression and functionality in mice.
Veau C; Faivre L; Tardivel S; Soursac M; Banide H; Lacour B; Farinotti R
J Pharmacol Exp Ther; 2002 Aug; 302(2):742-50. PubMed ID: 12130739
[TBL] [Abstract][Full Text] [Related]
14. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo.
Fellner S; Bauer B; Miller DS; Schaffrik M; Fankhänel M; Spruss T; Bernhardt G; Graeff C; Färber L; Gschaidmeier H; Buschauer A; Fricker G
J Clin Invest; 2002 Nov; 110(9):1309-18. PubMed ID: 12417570
[TBL] [Abstract][Full Text] [Related]
15. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
16. P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing.
Gustafson DL; Long ME; Bradshaw EL; Merz AL; Kerzic PJ
Cancer Chemother Pharmacol; 2005 Sep; 56(3):248-54. PubMed ID: 15856231
[TBL] [Abstract][Full Text] [Related]
17. Peptide-vector strategy bypasses P-glycoprotein efflux, and enhances brain transport and solubility of paclitaxel.
Blanc E; Bonnafous C; Merida P; Cisternino S; Clair P; Scherrmann JM; Temsamani J
Anticancer Drugs; 2004 Nov; 15(10):947-54. PubMed ID: 15514563
[TBL] [Abstract][Full Text] [Related]
18. Trametenolic acid B reverses multidrug resistance in breast cancer cells through regulating the expression level of P-glycoprotein.
Zhang Q; Wang J; He H; Liu H; Yan X; Zou K
Phytother Res; 2014 Jul; 28(7):1037-44. PubMed ID: 25289403
[TBL] [Abstract][Full Text] [Related]
19. Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model.
Fransson MN; Gréen H; Litton JE; Friberg LE
Drug Metab Dispos; 2011 Feb; 39(2):247-55. PubMed ID: 21056987
[TBL] [Abstract][Full Text] [Related]
20. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).
Sparreboom A; Scripture CD; Trieu V; Williams PJ; De T; Yang A; Beals B; Figg WD; Hawkins M; Desai N
Clin Cancer Res; 2005 Jun; 11(11):4136-43. PubMed ID: 15930349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
